US Patent Reform Bills And Jobs: Critical Timing, Critical Differences 04/03/2009 by Liza Porteus Viana, Intellectual Property Watch 1 Comment The United States patent reform bills offered up Tuesday fall well short of what is needed to protect innovation and intellectual property rights, say myriad small tech companies, large-cap manufacturers, pharmaceutical firms and inventors. In fact, they say, it even threatens jobs at a time when the economy is in desperate need of them. But proponents argue that it is precisely the type of measure needed to promote jobs, reduce lawsuits and poor patent quality that put a drag on innovation and the economy.
Innovation Policy: The Balance Between Standards and Patent Regulation 26/02/2009 by Intellectual Property Watch 11 Comments By Georg Greve Interconnectivity, commoditisation and increased reuse and recombination are key trends within the maturing information and communication technologies (ICT) industry that drive innovation and development. Harnessing the innovative and economic potential of the ICT sector depends on a variety of factors, including open innovation models, such as free software.
Path Forward For UN-Led Internet Governance Forum Discussed 26/02/2009 by Kaitlin Mara for Intellectual Property Watch Leave a Comment That there will be a future for the international Internet Governance Forum seems likely, though the form its future incarnation will take is not. Delegates to an open consultation on internet governance this week began to sort out some base modalities on how to evaluate the progress of the United Nations-led discussion venue, as a deadline approaches to decide whether and how the group will continue.
Drug Patent Linkage Is Subject Of Court Case, Dispute In India 25/02/2009 by Monika Ermert for Intellectual Property Watch 1 Comment Should national drug control bodies grant marketing licences to generic medicine companies only if their products do not possibly infringe existing patent rights? Yes, German pharmaceutical company Bayer told the High Court of Delhi last week when the court heard arguments in an ongoing court case on patent linkage.
Enforcement, Creative R&D Financing Priority Issues For Public Health in 2009 25/02/2009 by Kaitlin Mara for Intellectual Property Watch Leave a Comment The number and intensity of debates over the role of intellectual property rights in public health is set to increase in 2009. New leadership and new mandates for key intergovernmental organisations implemented last year have created opportunity for change. And while old debates over the balance between IP rights and access to health products are not going away, this year will see more exploration at the intergovernmental level of different systems to stimulate innovation.
Industry Pushes For Biosimilars Approval Process; Some IGOs Take Notice 24/02/2009 by Kiernan A. Murphy for Intellectual Property Watch and Kaitlin Mara for Intellectual Property Watch Leave a Comment Key players in the biotechnology industry are leading an effort to obtain global approval processes for generic biological medicines, which experts say could provide cheaper access to costly but widely prescribed and promising treatments.
欧盟有关知识产权的强硬规定被视为对贫困国家医药获得的威胁 24/02/2009 by David Cronin for Intellectual Property Watch Leave a Comment 布鲁塞尔 – 全球公共卫生活跃分子声称，欧盟执意要在一系列自由贸易协议中添加有关医药专利的强硬规定将会妨害发展中国家获得医药。
لأحكام التجارية القوية للاتحاد الأوروبي حول الملكية الفكرية تعتبر تهديدا على نفاذ البلدان الفقيرة إلى الأدوية 24/02/2009 by David Cronin for Intellectual Property Watch Leave a Comment ابروكسل- إن الجهود التي يبذلها الاتحاد الأوروبي لإدراج أحكام حول براءات المستحضرات الصيدلانية في سلسلة من اتفاقات التجارة الحرة التي يتفاوض حولها قد تشكل تهديدا على إمكانية الحصول على الأدوية في البلدان النامية، على حد قول الناشطين في مجال الصحة العامة على الصعيد العالمي.
Des dispositions renforçant la propriété intellectuelle dans certains accords de l’UE menacent l’accès aux médicaments dans les pays pauvres 24/02/2009 by David Cronin for Intellectual Property Watch Leave a Comment BRUXELLES – Selon certains activistes de la santé publique mondiale, les efforts de l’Union européenne (UE) pour intégrer des dispositions sur les brevets pharmaceutiques dans un certain nombre d’accords de libre échange en cours de négociation pourraient mettre en péril l’accès aux médicaments dans les pays en développement.
Las estrictas disposiciones comerciales de la UE sobre PI representan una amenaza para el acceso de los países pobres a los medicamentos 24/02/2009 by David Cronin for Intellectual Property Watch 1 Comment BRUSELAS- Los esfuerzos de la Unión Europea para introducir disposiciones firmes en materia de patentes farmacéuticas en una serie de acuerdos de libre comercio que está negociando podrían poner en peligro el acceso a los medicamentos en los países en desarrollo, según han afirmado activistas de la salud pública a nivel mundial.